Mohamed Naguib Attala

Title: Innovations of Mohamed Naguib Attala

Introduction

Mohamed Naguib Attala is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of neuroprotective therapies, holding a total of 8 patents. His work focuses on developing methods to treat neuroinflammatory and neurodegenerative diseases.

Latest Patents

Attala's latest patents include innovative methods involving CB2 receptor agonists. One patent describes a method of treating or preventing neuroinflammatory and/or neurodegenerative diseases by administering a pharmaceutically effective amount of a CB2 receptor agonist. This agonist can be a compound according to a specific formula or a pharmaceutically acceptable salt thereof. The administration of the CB2 receptor agonist activates CB2 receptors in microglia, potentially restoring synaptic plasticity, cognition, and memory in subjects with elevated levels of amyloid-β peptide in the brain.

Another patent also focuses on neuroprotective CB2 receptor agonists, detailing a similar method for treating neuroinflammatory and neurodegenerative diseases. This patent emphasizes the activation of CB2 receptors in microglia and its effects on cognitive functions in affected subjects.

Career Highlights

Throughout his career, Attala has worked with esteemed institutions such as the Cleveland Clinic Foundation and the University of Texas System. His research has significantly advanced the understanding of neuroprotective mechanisms and therapeutic approaches.

Collaborations

Attala has collaborated with notable professionals in his field, including Philippe Diaz and David L. Brown. These collaborations have contributed to the development of his innovative patents and research.

Conclusion

Mohamed Naguib Attala's work in neuroprotective therapies showcases his dedication to advancing medical science. His patents reflect a commitment to improving treatment options for neuroinflammatory and neurodegenerative diseases.